Anonymous
Guest
Anonymous
Guest
The KOS acquisition was a nightmare because Abbott tried to integrate KOS immediately and laid off their own instead, a lot of KOS quit and Abbott was surprised, so Solvay went down differently. Solvay was left alone with same territories, managers etc. No one was laid off from Solvay and Abbott seemed pleased with this process so I predict same with Shire. Solvay folks are now Abbvie so could be taking a hit, but most likely Shire will stay somewhat the same if they are following the Solvay acquisition model. The metabolics team (old Solvay) is overstaffed in most areas.